World Rural Health Conference
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 80
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2017  |  Volume : 6  |  Issue : 1  |  Page : 11-18

Diabetes and Ramadan: A concise and practical update


1 Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, Buckinghamshire, UK
2 Department of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan
3 Department of Pathology, Faculty of Medicine and Health Sciences, Nile Valley University, Atbara, Sudan
4 Department of Medicine, Faculty of Medicine and Health Sciences, Nile Valley University, Atbara, Sudan
5 Department of Surgery, Whiston Hospital, Merseyside, UK
6 Department of Pathology, Faculty of Medicine, University of Medical Sciences and Technology, Khartoum, Sudan

Correspondence Address:
Mohamed H Ahmed
Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, Buckinghamshire
UK
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2249-4863.214964

Rights and Permissions

Despite the fact that the month of Ramadan includes 29–30 days and the duration of fasting for each day can last for between 12 and 16 h, it was estimated that a large number of individuals with diabetes do fast during Ramadan. In light of recent advancement of new pharmacological agents, drugs such as vildagliptin, sitagliptin, and liraglutide were found to be safe to use during this month of fasting. These therapeutic agents can also be used in combination with metformin. The use of sulfonylureas, in most of the recent guidelines about diabetes and Ramadan, seems not to gain much support due to the risk of hypoglycemia. In this review, we also addressed the use of insulin injection, insulin pump, and education before, during, and after Ramadan. Further research is needed to determine (i) the therapeutic benefit of new antidiabetic agents and (ii) the benefit of new technologies for the treatment of diabetes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed294    
    Printed3    
    Emailed0    
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal